Please login to the form below

Not currently logged in
Email:
Password:

Emergent BioSolutions

This page shows the latest Emergent BioSolutions news and features for those working in and with pharma, biotech and healthcare.

Emergent inks $174m deal with AstraZeneca to manufacture COVID-19 vaccine

Emergent inks $174m deal with AstraZeneca to manufacture COVID-19 vaccine

Follows initial deal agreed in June. US-based CDMO Emergent BioSolutions has agreed a deal with AstraZeneca to expand manufacturing of the latter's potential COVID-19 vaccine. ... According to Emergent, the deal is valued at approximately $174m and runs

Latest news

  • Shake-up at GSK could claim antibiotics unit and UK facilities Shake-up at GSK could claim antibiotics unit and UK facilities

    In the meantime the company has also announced a product divestment - selling its anthrax prevention drug raxibacumab to Emergent BioSolutions for around $96m. ... The FDA-approved therapy is tied to a $130m supply deal with the US government, which will

  • GSK: We had a social responsibility to work on Ebola GSK: We had a social responsibility to work on Ebola

    More recently it was revealed this week that will be working with Emergent BioSolutions on a phase I trial that would addd that firm's Ebola vaccine candidate as a booster

  • TB vaccine disappoints, but others in the pipeline TB vaccine disappoints, but others in the pipeline

    Helen McShane of the University of Oxford in the UK. The trial was sponsored by non-profit vaccines company Aeras, the Wellcome Trust and the Oxford-Emergent Tuberculosis Consortium (OETC), a ... joint venture between the University of Oxford and

  • Biologics buoyant

    Phase I . 28. Oxford Biomedica/Emergent BioSolutions. Prime boost technology - vaccines.

More from news
Approximately 1 fully matching, plus 4 partially matching documents found.

Latest Intelligence

  • Deal Watch table for August 2014 Deal Watch table for August 2014

    187. Emergent BioSolutions/ Morphosys. Licence, joint development &commercialisation. MOR209/ES414, anti-PSMA/anti-CD3 bi-specific antibody targeting prostate cancer (preclinical).

  • Deal Watch table for April 2013 Deal Watch table for April 2013

    60. Bracco Diagnostics/ Emergent BioSolutions. Asset purchase. Healthcare Protective Products Division.

  • Interview: Charles Mgone, EDCTP Interview: Charles Mgone, EDCTP

    But it doesn't stop the contagious form acquired by adults. So we are working with Emergent BioSolutions and Aeras, a non-profit product developer, as well as institutions in the

More from intelligence
Approximately 0 fully matching, plus 3 partially matching documents found.

Latest appointments

  • Barry Labinger joins Biothera Pharmaceutical Barry Labinger joins Biothera Pharmaceutical

    Labinger has nearly three decades of pharmaceutical and biotech industry experience, with roles at Emergent BioSolutions, Human Genome Sciences, 3M Pharmaceuticals and Immunex. ... Labinger most recently served as executive vice president and president,

More from appointments
Approximately 0 fully matching, plus 1 partially matching documents found.

PMEA Awards 2020

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Empowering Strategic Performance Ltd

OUR GOAL: To help clients Metamorph™ Science into Action that changes healthcare to improve the lives of patients. Empowering Strategic...

Latest intelligence

Mistrust in medical research: a patient perspective
The recent development of several COVID-19 vaccines has placed medical research firmly in the spotlight, highlighting public confusion and misinformation about clinical trials. Patient advocate, Trishna Bharadia reveals what the...
Real-world evidence: breaking boundaries in rare disease
Generating data for drug launches is a challenging process. In rare diseases, with small patient populations and high unmet need, evidence generation is even more complex. Consultant Sarah Poole and...
The heavy toll of COVID-19 on cancer patients
We all know that finding and treating cancer early saves lives. During the COVID-19 pandemic, oncology treatments paused while cancer continued to spread. So, what has been the impact of...

Infographics